General MedicationsINJECTIONGeneric
HYDASE
HYALURONIDASE
Standard Dose
150 UNITS/ML
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Discontinued
Summary
Approval overview HYDASE is listed in Drugs@FDA under application 021716 (BLA).
Review priority: STANDARD Marketing status: Discontinued Active ingredient HYALURONIDASE Form and strength INJECTABLE;INJECTION - 150 UNITS/ML Sponsor AKORN INC Submission history Latest submission status date: 2015-11-05 00:00:00.
Structured Monograph
Clinical summary
Approval overview HYDASE is listed in Drugs@FDA under application 021716 (BLA). Review priority: STANDARD Marketing status: Discontinued Active ingredient HYALURONIDASE Form and strength INJECTABLE;INJECTION - 150 UNITS/ML Sponsor AKORN INC Submission history Latest submission status date: 2015-11-05 00:00:00. Submission type: SUPPL.
Monitoring
- • Marketing status: Discontinued
- • Review priority: STANDARD
Interaction Notes
- No interaction notes stored yet.